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A B S T R A C T
Biorelevant ﬂuids are required to enable meaningful in vitro experimental determinations of the biopharma-
ceutical properties of inhaled medicines, e.g. drug solubility, particle dissolution, cellular uptake. Our aim was to
develop a biorelevant simulated lung ﬂuid (SLF) with a well-deﬁned composition and evidence-based directions
for use. The SLF contained dipalmitoylphosphotidylcholine, dipalmitoylphosphatidylglycerol, cholesterol, al-
bumin, IgG, transferrin and antioxidants. Freshly made SLF had pH 7.2, viscosity 1.138×10−3 Pa s, con-
ductivity 14.5 mS/m, surface tension 54.9mN/m and density 0.999 g/cm3. Colour, surface tension and con-
ductivity were the most sensitive indicators of product deterioration. The simulant was stable for 24 h and
48 h at 37 °C and 21 °C, respectively, (in-use stability) and for 14 days when stored in a refrigerator (storage
stability). To extend stability, the SLF was vacuum freeze-dried in batches to produce lyophilised powder that
can be reconstituted readily when needed at the point of use. In conclusion, we have reported the composition
and manufacture of a biorelevant, synthetic SLF, provided a detailed physico-chemical characterisation and
recommendations for how to store and use a product that can be used to generate experimental data to provide
inputs to computational models that predict drug bioavailability in the lungs.
1. Introduction
The factors that govern respiratory and systemic exposure to drugs
delivered as inhaled medicines deﬁne their ‘inhalation biopharmaceu-
tics’ [1]. The major factors determining the bioavailability of drugs
delivered as inhaled medicines are lung dose and aerodynamic particle
size distribution, which determines regional deposition [2]. Following
deposition, the interactions of aerosol particles or drug with competing
lung clearance mechanisms determine (i) drug bioavailability in the
lungs; (ii) the rate and extent of absorption to the systemic circulation
[3]. Drug solubility is a key consideration in the development of inhaled
medicines, including drug design/discovery [4,5], formulation [6] and
toxicokinetics [7]. The importance of solubility and dissolution in
predicting the pharmacokinetics of some orally inhaled drug products
has been demonstrated convincingly [8] and particle-lung ﬂuid inter-
actions have been suggested to impact on inhaled drug delivery [9]. For
example, excipients such as glycerol in licenced inhaled medicines have
been shown to inﬂuence aerosol particle dissolution [10,11] and in-
teractions between inhaled nanomaterials and lung ﬂuid have been
investigated [12,13]. Study of all these phenomena require biorelevant
ﬂuids in which to make meaningful in vitro experimental measure-
ments.
Since the ﬁrst biological destination of inhaled medicinal aerosols is
the respiratory tract lining ﬂuid (RTLF) in which they deposit, it is
surprising how little is published about models of RTLF in which to
study interactions with particles, e.g. requirements for ﬂuid composi-
tion or critical attributes. A variety of approaches have been adopted to
simulate RTLF, including use of surfactant solutions, e.g. Tween 80 or
sodium dodecyl sulphate in phosphate buﬀered saline [8,10], phos-
pholipid-containing ﬂuids [14,15] or diluted surfactant replacement
products, such as Alveofact, Exosurf, Curosurf or Survanta [16,17].
Recently, a synthetic simulated lung ﬂuid (SLF) based on human lung
ﬂuid composition has been characterised in terms of its vesicular
structure and particle size, surface pressure and assessed for bio-
compatibility with A549 alveolar epithelial cells [18]. A similar SLF has
been reported for applications in environmental toxicology [19], but
here we provide a more detailed validation and characterisation of a
‘base’ SLF that reﬂects human lung ﬂuid composition and can be in-
corporated into in vitro experimental models or adapted for speciﬁc
applications in pharmaceutical science, e.g. if particular surfactant
proteins, speciﬁc metabolic activities or model inﬂammatory disease
states are of interest.
If a simulant is to prove useful, it must be readily available, con-
venient, economic and have well deﬁned conditions for storage and use.
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For a complex aqueous ﬂuid with components susceptible to chemical
degradation, physical instability or microbial spoilage, freeze-drying
provides an excellent means of preservation. Desiccation will protect
the SLF since it minimises chemical reactions, e.g. the rate of lipid
hydrolysis during storage [20], and deters microbiological growth.
Accordingly, freeze-drying the SLF would allow batch manufacture in a
form that has an extended use-by date and is easily handled and
transported for reconstitution at its place and time of use [21,22].
This study provides a complete description of the design and man-
ufacture of the biorelevant SLF of Kumar and co-workers [18] and re-
ports a suite of physicochemical parameters that characterise the pro-
duct and can be used as sensitive indicators of SLF stability. The
stability of SLF was investigated to deﬁne appropriate conditions for its
storage and use. We also investigated freeze-drying the lung ﬂuid si-
mulant to produce a lyophilised powder with long term stability that
can be reconstituted when required at the point of use.
2. Materials and methods
The 25mg/mL stock solutions of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-
rac-glycerol) sodium salt (DPPG), both>99% purity, were obtained
from Avanti Polar Lipids, Inc. (Alabama, USA). Reagent-grade puriﬁed
human immunoglobulin (IgG), lyophilised human serum albumin,
Bioreagent-grade transferrin, cholesterol, ascorbate, urate, certiﬁed
reference material-grade glutathione and BioReagent grade gentamicin
solution were supplied by Sigma-Aldrich Company Limited (Dorset,
UK). Hanks' Balanced Salt Solution (HBSS), phenol red-free, was also
supplied by Sigma-Aldrich and consisted of: 0.19 g/L calcium chloride
dihydrate, 0.09 g/L magnesium sulphate anhydrous, 0.40 g/L
Abbreviation section
RTLF Respiratory Tract Lining Fluid
SLF Simulated Lung Fluid
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
DPPG 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol)
sodium salt
IgG Immunoglobulin G
HBSS Hank's Balanced Salt Solution
TLC Thin Layer Chromatography
TGA Thermogravimetric Analysis
Fig. 1. A) Manufacturing steps of simulated lung ﬂuid (SLF), B) Freeze-drying and reconstitution steps of SLF, C) Composition of SLF and D) Images of the original
and the reconstituted SLF.
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potassium chloride, 0.06 g/L potassium phosphate, 0.35 g/L sodium
bicarbonate, 8.00 g/L sodium chloride, 0.05 g/L sodium phosphate di-
basic, and 1.00 g/L D-Glucose. HPLC-grade chloroform and methanol
was supplied by Fischer Chemicals (Loughborough, UK). 25% ammo-
nium hydroxide, sodium chloride and 2M hydrochloric acid solutions
were obtained from Sigma-Aldrich Company Limited (Dorset, UK).
2.1. Preparation of SLF
SLF consisted of the key components found in healthy human RTLF,
the major soluble proteins, the abundant lipids and the antioxidants
that were identiﬁed in a study by Bicer [23]. The proteins were al-
bumin, IgG and transferrin, and the lipids were DPPC, DPPG and cho-
lesterol. The preparation method was optimised into two stages, with
the manufacture of a liposomal dispersion followed by addition of the
proteins (Fig. 1). To prepare the liposomal component, 1.92mL DPPC
and 0.2 mL DPPG, from 25mg/mL stock solutions in chloroform were
combined in a bijou bottle, with 5 μL of cholesterol from a 200mg/mL
stock solution in chloroform also added. The mixture was stirred gently
and the chloroform evaporated under a stream of nitrogen gas for
30min (suﬃcient to ensure that the lipid ﬁlm was solvent free) to
produce a thin ﬁlm of lipids. The proteins were added to the lipid ﬁlm
in aliquots of aqueous stock solutions: 4 mL of albumin (88mg/mL),
4 mL of IgG (26mg/mL) and 1mL of transferrin (15mg/mL). To re-
present lung antioxidant levels, 88.5 μL of the following antioxidant
stock solutions were added: 10mM ascorbate, 10mM glutathione, and
5mM urate in the HPLC-grade water. The mixture was vortexed for
5min. Using an ultrasonicator/probe for 10min at a pulse of 10 am-
plitude, the lipids were dispersed into the solution in the form of
polydisperse multilamellar liposomes. Finally, 10 μL of 50mg/mL
gentamicin was added, followed by 775 μL of HBSS under gentle agi-
tation.
2.2. Characterisation of SLF
The SLF was characterised in this study in terms of its pH, density,
viscosity, conductivity and surface tension. The pH was measured using
a pH probe (pH level 2 InoLab, WTW, Germany). The density of SLF was
measured using a density meter (DMA 35, Anton Paar, UK) whereby the
inverted capillary cell was ﬁlled with approximately 5mL of SLF.
Distilled water was used as the reference. The viscosity was measured
using the Automated Micro Viscometer (AMVn 320, Anton Paar, UK). A
1.6 mm diameter capillary, containing a 1.5mm diameter ball was
ﬁlled with 400 μL SLF, sealed with a luer cap and measurements made
with the capillary tilted at 50°, 60° and 70°. The conductivity of SLF was
measured using a conductivity probe and meter (Jenway A520, Cole-
Parmer, UK), calibrated using 0.01M potassium chloride solution,
providing a value of 1413 ± 1 μS/cm. The surface tension of SLF was
measured using a torsion balance (Model OS, TBS, UK), using distilled
water as the reference sample which gave a surface tension value of
72.5 ± 0.5mN/m. A 4 cm circumference platinum ring was immersed
approximately 0.5 cm into SLF ring and the force required for with-
drawal of the platinum ring from the surface of the ﬂuid was recorded
as the surface tension. All measurements were conducted in triplicate at
ambient temperature.
2.3. Freeze-drying of SLF
SLF, 10mL solution, was prepared in a SCHOTT tubular glass freeze
drying vial. Samples were frozen overnight at −20 °C and then placed
into a vacuum freeze-drying system (Lyotrap, LTE Scientiﬁc Ltd, UK)
with condenser temperature −45 °C and a vacuum of 0.060mbars for
48 h. Thermogravimetric analysis (Discovery TGA, TA Instruments, UK)
was used to analyse the residual moisture content in the freeze-dried
SLF powder, heating the sample at a heating rate of 10 °C/min to a
maximum of 200 °C. The powder was reconstituted with 10mL de-
ionised water and compared to fresh SLF using the physico-chemical
parameters described in section 2.2.
2.4. Stability of SLF
SLF stability was determined for samples stored in the fridge (at
4 °C), at room temperature (20 °C) and at human physiological tem-
perature (37 °C). The stability was assessed by analysing pH, viscosity,
conductivity and surface tension after their storage for 0, 1, 2, 3, 4, 7,
14 and 28 days using the methods described above. The appearance and
colour of SLF were also analysed visually and via measurements of the
mean grey value, using the Image J software (Java 1.8.0–25, version
1.51p). Using the software, the images captured were ﬁrst converted to
‘8-bit’ prior to obtaining the mean grey value. All data were recorded as
the mean of three measurements ± SD.
Lipid degradation was evaluated using one-dimension thin layer
chromatography (TLC). The lipid components were extracted from the
SLF ﬂuid, using an adapted version of the method detailed by Bligh and
Dyer [24]. Brieﬂy, 1mL SLF sample was centrifuged at 13,000 rpm for
10min to sediment out the lipids and proteins. To the pellet obtained,
1mL of a mix consisting of chloroform: methanol [2:1] and 0.26mL,
was added and mixed to form a single phase. The sample was left to
incubate with gentle agitation for 90min at 37 °C. Acidiﬁed saline
(150mM sodium chloride adjusted to pH 2 with hydrochloric acid),
0.5 mL, was added and vortex mixed for 5min followed by cen-
trifugation at 2000 rpm for 15min (Biofuge Pico, Jencons-PLS Scien-
tiﬁc, UK). The aqueous phase was removed and 0.25mL methanol and
0.25mL acidiﬁed saline was added to the remaining organic phase. This
was vortex mixed and centrifuged again at 2000 rpm for 15min, then
the aqueous layer was removed and the organic solvent evaporated to
concentrate the lipids.
To analyse the isolated lipids by TLC, the sample was spotted ap-
proximately 1 cm from the bottom of a plain silica gel 60 TLC plate. The
plate was transferred to a glass TLC tank containing 1 cm depth of the
mobile phase, consisting of chloroform, methanol and 25% ammonium
hydroxide solution at a ratio of 65:25:10. When the mobile phase
reached three-quarters way up the plate the lipids were visualised as
yellow spots using potassium permanganate stain. The retardation
factor (RF) was calculated as the distance travelled by centre of the spot
divided by the distance travelled by the solvent front. A calibration
between spot intensity (using the mean grey value) and concentration
of DPPC and DPPG was established and used to estimate the content of
lipid in the SLF.
2.5. Statistical analysis
The physicochemical properties were derived from three in-
dependent batches; the data for the stability study was for 3 vials from a
single batch of SLF. One-way ANOVA or paired sample T-test was ap-
plied, using the IBM SPSS version 24 software, to determine the sta-
tistical signiﬁcance of results. Data was statistically signiﬁcant when
p≤ 0.05.
3. Results and discussion
3.1. Composition and characterisation of SLF
The composition of the simulated lung ﬂuid was identical to that
reported previously [18] and was designed to provide a simulant that
trades oﬀ the biorelevance of featuring the full complexity of lung
lining ﬂuid with the pragmatic need for a simulant that can be manu-
factured economically, reproducibly and is ﬁt for the majority of ap-
plications in inhaled medicines biopharmaceutics. Although DPPC,
which contributes approximately 80% w/v of surfactant phospholipids,
is often used as a sole representative phospholipid component in model
lung ﬂuids, for physiological relevance other lipid components were
M. Hassoun et al. Journal of Drug Delivery Science and Technology 47 (2018) 485–491
487
incorporated including DPPG which represents approximately 10% of
total phospholipids, and cholesterol which accounts for 5–10% lipids
and has been shown to have a stabilising role in bilayer structures.
Although lung ﬂuid contains a mixture of saturated and unsaturated
lipid, the unsaturated species were avoided as being more susceptible to
oxidation. Urea corrected total protein concentration measured in
human lavage samples is in the range 17.9 ± 8.6mg/mL [23], but due
to the limited commercial availability and consistency of some human
protein components, e.g. SP-A, SP-B, SP-C, IgA and A1TA, the total
proteins used in the preparation of SLF was 12.9 mg/mL. Biorelevant
concentrations of antioxidants were included to promote the reported
biocompatibility of the SLF with respiratory epithelial cells [18].
Appearance and four physicochemical properties were used to
characterise SLF: colour, pH, conductivity, viscosity and surface tension
(Table 1). The pH of SLF was pH 7.2, buﬀered by the use of HBSS as a
base medium. The pH the human respiratory tract is subject to some
variability, e.g. pH 6.3 (range 5.2–8.1) in the nasal cavity [25], pH
6.9–9.0 in the trachea [26] and suggested to be more acidic in in-
ﬂammation and infection [26]. The essential inorganic ions of the HBSS
provide a physiological salt composition, tonicity (280 mOsM) and are
responsible for the high conductivity in comparison to de-ionised water
matching the properties of lung lining ﬂuid in healthy subjects [27].
The surface tension of SLF, 55mN/m, was lower than that of water
which was measured to be 72mN/m. DPPC is the most surface-active
molecule in the pulmonary surfactant mix and signiﬁcantly reduces
surface tension [28]. Pulmonary surfactants in the epithelial lung lining
form a lipid-rich ﬁlm with a signiﬁcantly reduced surface tension from
70mN/m at the upper airways to near 0mN/m at the alveoli [29,30].
The absence of surfactant proteins in SLF (particularly surfactant pro-
tein B), which are present in epithelial lung lining ﬂuid result in the
higher surface tension value than would otherwise be anticipated for a
lung ﬂuid simulant [29,31]. Surfactant proteins also play a role in ﬂuid
viscosity, whereby surfactant protein-C (SP-C) interacts with the lipids
to produce high surface viscosity [32]. Despite the absence of SP-C in
SLF, the viscosity of SLF was higher than that of simple aqueous solu-
tions, which was attributed to the presence of protein macromolecules
and complex lipids in their physiological concentrations. The absence of
specialist surfactant proteins (SP) limits the application of the SLF for
some specialist immunological applications, e.g. where SP A and D are
important in host-defence or biophysical studies where SP C and B have
important roles in the complex membrane network in the lung lining
ﬂuid sub-phase.
3.2. Freeze-dried SLF
For freeze drying to be successful, a dry ﬂuﬀy lyophilised powder
should be produced which can easily be reconstituted to possess phy-
siochemical properties that match the original sample [33]. Without
addition of cryoprotectants, lyophilised liposomal powders are often
compact, clumpy and diﬃcult to reconstitute [20,34,35]. SLF was
freeze-dried successfully without the need for additional formulation
components to act as cryoprotectants; the powder produced was ﬂuﬀy
and easy to reconstitute with water to restore the appearance and
physicochemical properties of the SLF (Table 1). The reconstituted
freeze-dried formulation was identical to the freshly made solution
except for a small statistically signiﬁcant increase in pH (one-way
ANOVA, p≤ 0.05), which can be readily corrected. Although water is
predominantly neutral in pH, the use of diﬀerent grades for recon-
stitution, e.g. distilled water, de-ionised water, HPLC-grade water or
ultrapure water, may result in variations in pH [36].
While freeze-drying can improve the storage stability of liposomal
formulations, it has been recognised that the process can also cause
damage to the liposome structures which are exposed to stress condi-
tions, e.g. excessive dryness, which can pierce the liposomes or pre-
dispose them to aggregation [20,37,38]. TGA indicated that
4.42 ± 0.15% moisture was retained in the lyophilised powder
produced. In combination, the avoidance of excessive dryness, the
likelihood that formulation components provide a degree of cryopro-
tection and the polydisperse multivesicular nature of the liposomes
rendered the SLF resistant to destabilising stress factors under the
freeze-drying process parameters employed, i.e. freezing rate, freezing
temperature and processing time.
3.3. Stability of SLF
Preliminary studies showed that appearance and four physico-
chemical properties were stability-indicating; these were used to eval-
uate SLF over 28 days at three temperatures, 4, 20 and 37 °C (Fig. 2).
The assays were congruous in detecting the conditions and time at
which SLF began to degrade and in proﬁling temporal stability at each
storage temperature. Although the use of dynamic light scattering was
considered as a means to study any changes in the polydispersity and
the size distribution of the structures in SLF, in previous studies [18] the
extent of background scattering by the multi-molecular protein ag-
gregates present in the ﬂuid has complicated interpretation of results
and we found it was not suitable as a stability test.
In terms of appearance, SLF was peach coloured when freshly made.
This was quantiﬁed using Image J as a mean grey value on a scale
where 0 corresponds to black and a value of 255 corresponds to white
(Fig. 2A). SLF lightened in colour visibly, becoming whiter by day 2,
with the mean grey value rising from 168.5 ± 0.4 to 174.5 ± 0.1 at
20 °C and 169.7 ± 0.3 to 175.3 ± 0.3 at 37 °C. At 4 °C, the mean grey
value was unchanged at day 14 and the only increased from
168.9 ± 0.3 to 175.9 ± 0.3 at day 28. The pH and viscosity of the SLF
samples stored at 20 and 37 °C also began to decrease after day 2 of
storage (Fig. 2B and C). Conductivity and surface tension were aﬀected
similarly (Fig. 2D and E), at 37 °C there was a reduction of surface
tension from 54.6 ± 0.5mN/m to 53.0 ± 0.2mN/m at day 2, which
continued to decrease until 28 days (One-way ANOVA, p≤ 0.05).
Liposomes in aqueous dispersions tend to be relatively unstable and
these results were consistent with changes that occur to lipids at ele-
vated temperature or over periods of time, e.g. hydrolysis or lipid
peroxidation [39–41]. Although antioxidants are present in SLF in small
quantities, they are not fully protective and ascorbate may even cata-
lyse the oxidation of phospholipids in solvent systems [42]. Degrada-
tion of the phospholipids can reduce pH as lipids dissociate into their
constituent fatty acids [43]. Metal cations, such as the sodium ion
present in DPPG and the quaternary ammonium ion in DPPC, can
participate in reactions that produce a sharp decrease in viscosity [43].
Hydrolysis of phospholipids produces two main lysoforms, with the 1-
acyl lysoform being predominant [44]. Higher levels of lipids reduce
the surface tension of protein-containing solutions [45] and the elec-
trical conductivity of aqueous solutions [46].
TLC analysis was used to probe lipid stability further. Potassium
permanganate was used to detect phospholipids by oxidising the
phosphorus groups giving a distinctive colour change from pink to
yellow. At day 0, TLC of SLF revealed two spots with RF values of
0.66 ± 0.01 and 0.85 ± 0.01, which were identiﬁed as DPPC and
DPPG, respectively, by comparison to reference standards (data not
Table 1
Physicochemical properties of simulated lung ﬂuid (SLF) when freshly manu-
factured and when reconstituted after freeze-drying. All measurements made at
25 °C, data represent mean ± SD (n= 3).
Physicochemical property SLF before freeze-dried SLF after freeze-dried
Appearance [mean grey value] 168.6 ± 0.4 168.6 ± 0.1
pH 7.2 ± 0.0a 7.7 ± 0.1a
Conductivity [mS/m] 14.5 ± 0.1 14.6 ± 0.2
Viscosity [Pa.s x 10−3] 1.138 ± 0.008 1.111 ± 0.015
Surface Tension [mN/m] 54.9 ± 0.3 55.6 ± 0.7
a Diﬀerence is signiﬁcant (T-test, p≤ 0.05).
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shown). From day 3 and day 2, SLF stored at 20 °C and 37 °C exhibited
an additional spot with RF value of 0.48 ± 0.01, indicating presence of
a lipid hydrolysis product. The lipidomic analysis which would be
needed to identify the lipid species is beyond the scope of this study, but
TLC was used for quantitative determination [47] using image analysis
to provide a semi-quantitative measure of spot intensity for DPPC and
DPPG. For SLF stored at 20 °C, DPPC concentration fell by approxi-
mately 15% and DPPG concentration fell by 25% by day 3. For SLF
stored at 37 °C, both DPPC and DPPG concentrations decreased by ap-
proximately 20% by day 2. In contrast, less than 10% loss of DPPC and
DPPG was measured in SLF stored at 4 °C.
3.4. Recommendations for use of SLF
SLF can be stored in a refrigerator for 2 weeks based on observations
that the appearance, pH, viscosity, conductivity and surface tension
remained constant for 14 days at 4 °C, and signiﬁcant changes in SLF
characteristic do not become evident until day 28 (One-Way ANOVA,
p < 0.05) (Table 2). At 20 °C, changes in the SLF characteristics only
became signiﬁcant after 3–4 days of storage, indicating that SLF is
stable for 48 h and can be used in laboratory experiments, e.g. solubility
or dissolution tests, carried out at room temperature. At 37 °C, changes
in SLF characteristics became signiﬁcant at day 2, indicating that in
vitro experiments which involve cell culture or the use of physiological
temperature should be restricted to 24 h. Deteriorated SLF can inﬂu-
ence in vitro assay results, for example FP solubility increases from
2.20 ± 0.29 μg/mL in freshly prepared SLF to 6.80 ± 0.55 μg/mL in
SLF stored at 37 °C for 7 days. In contrast, FP solubility was identical in
freshly prepared compared to freeze dried and reconstituted SLF.
The stability of the lyophilised powder is currently under
Fig. 2. Stability assessment of simulated lung ﬂuid (SLF) after its storage at 4, 20 and 37 °C for 0, 1, 2, 3, 4, 7, 14 and 28 days: A) Colour, B) pH, C) viscosity, D)
conductivity, and E) surface tension. Data expressed as mean ± SD (n= 3).
Table 2
The day at which the simulated lung ﬂuid (SLF) changed with regards to its
appearance and physicochemical properties (tested at days 1, 2, 3, 4, 7, 14, 28)
under storage at 4, 20 and 37 °C.
Physicochemical property Day at which there is a signiﬁcant diﬀerencea from
day 0 [day]
4 °C 20 °C 37 °C
Appearance [mean grey value] 28 3 2
pH 28 3 3
Conductivity [mS/m] 28 3 2
Viscosity [Pa.s x 10−3] 28 4 3
Surface Tension [mN/m] 28 4 2
Stability 14 days 2 days 1 day
a Signiﬁcance determined by One-way ANOVA, p≤ 0.05.
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investigation using the assays described herein. In an ongoing stability
study of the lyophilised powder stored at 4, 20 and 37 °C, the appear-
ance, pH, viscosity, conductivity and surface tension in the recon-
stituted ﬂuid are unchanged after 6 months of storage (Fig. 3) with no
chemical changes to the lipids detected by TLC. Thus, improved stabi-
lity of lyophilised liposomal formulations in contrast to the aqueous
formulations and thus allows for a longer-term storage of material.
Lyophilisation clearly increases the shelf-life of liposomes, preserving it
in a dry form that can easily be reconstituted with water immediately
prior to use.
4. Conclusion
A SLF of biorelevant composition was characterised and shown to
possess physicochemical properties comparable to those of RTLF. The
simulant was determined to be stable for 24 and 48 h at 37 and 20 °C,
respectively (in-use stability) and for 14 days when stored in a re-
frigerator (storage stability). Colour, surface tension and conductivity
were the most sensitive indicators of product deterioration. The SLF can
be freeze-dried which provides a means of prolonged storage. Initial
data indicates the stability of the freeze-dried preparation at room
temperature for up to 3 months, with studies ongoing. This work de-
scribes a readily available, biorelevant SLF that can be used for in vitro
investigations in the ﬁeld of inhalation biopharmaceutics, e.g. the so-
lubility of inhaled compounds, the dissolution of inhaled medicines and
the interaction of aerosol drugs or particles with lung cells.
Experimental in vitro data such as this is increasingly in demand to
provide inputs to computational models that predict (i) drug bioavail-
ability in the lungs; (ii) the rate and extent of absorption to the systemic
circulation [3].
Conﬂict of Interest
There are no known conﬂicts of interest associated with this pub-
lication and there has been no signiﬁcant ﬁnancial support for this work
that could have inﬂuenced its outcome.
Acknowledgement
Mireille Hassoun was supported by a BBSRC-CASE studentship (BB/
K012762/1) hosted at King's College London, and Orchid numbers for
Ben Forbes 0000-0001-8193-6107, Richard D. Harvey 0000-0003-
Fig. 3. Stability assessment of freeze-dried simulated lung ﬂuid (SLF) after its storage at 4, 20 and 37 °C for 0, 7, 28, 72 and 168 days: A) Colour, B) pH, C) viscosity,
D) conductivity, and E) surface tension. Data expressed as mean ± SD (n= 3).
M. Hassoun et al. Journal of Drug Delivery Science and Technology 47 (2018) 485–491
490
3625-4654, and Paul Royall 0000-0002-7101-2776.
References
[1] C. Ehrhardt, Inhalation biopharmaceutics: progress towards comprehending the
fate of inhaled medicines, Pharm. Res. (N. Y.) 34 (2017) 2451–2453.
[2] B. Forbes, P. Backman, D. Christopher, M. Dolovich, L. Bing, B. Morgan, In vitro
testing for orally inhaled products: developments in science-based regulatory ap-
proaches, AAPS J. 17 (2015) 837–852.
[3] P. Bäckman, A. Sumit, W. Couet, B. Forbes, W. Kruijf, A. Paudel, Advances in ex-
perimental and mechanistic computational models to understand pulmonary ex-
posure to inhaled drugs, Eur. J. Pharmaceut. Sci. 113 (2018) 41–52.
[4] C.D. Edwards, C. Lusconbe, P. Eddershaw, E.M. Hessel, Development of a novel
quantitative structure-activity relationship model to accurately predict pulmonary
absorption and replace routine use of the isolated perfused respiring rat lung model,
Pharmaceut. Res. 33 (11) (2016) 2604–2616.
[5] J.G. Weers, Enhanced design of inhaled therapeutics: what does the future hold?
Ther. Deliv. 7 (2016) 145–148.
[6] J.E. Hastedt, P. Bäckman, A.R. Clark, W. Doub, A. Hickey, G. Hochhaus, P.J. Kuehl,
C. Lehr, P. Mauser, J. McConville, R. Niven, M. Sakagimi, J.G. Weers, Scope and
relevance of a pulmonary biopharmaceutical classiﬁcation system AAPS/FDA/USP
Workshop March 16-17th, 2015 in Baltimore, MD, AAPS Open 2 (1) (2016) 1.
[7] R.M. Jones, N. Neef, Interpretation and prediction of inhaled drug particle accu-
mulation in the lung and its associated toxicity, Xenobiotica 42 (1) (2012) 86–93.
[8] S. Bhagwat, U. Schilling, M. Chen, X. Wei, R. Delvadia, M. Absar, B. Saluja,
G. Hochhaus, Predicting pulmonary pharmacokinetics from in vitro properties of
dry powder inhalers, Pharmaceut. Res. 34 (12) (2017) 2541–2556.
[9] S.C. Das, P.J. Stewart, The inﬂuence of lung surfactant liquid crystalline nanos-
tructures on respiratory drug delivery, Int. J. Pharm. 514 (2) (2016) 465–474.
[10] F. Buttini, M. Miozzi, A.G. Balducci, P.G. Royall, G. Brambilla, P. Colombo,
R. Bettini, B. Forbes, Diﬀerences in physical chemistry and dissolution rate of solid
particle aerosols from solution pressurised inhalers, Int. J. Pharm. 465 (1–2) (2014)
42–51.
[11] C.I. Grainger, M. Saunders, F. Buttini, R. Telford, G.P. Martin, S.A. Jones, B. Forbes,
Critical characteristics for corticosteroid solution metered dose inhaler bioequiva-
lence, Mol. Pharm. 9 (2012) 563–569.
[12] M. Beck-Broichsitter, A. Bohr, C.A. Ruge, Poloxamer-decorated polymer nano-
particles for lung surfactant compatibility, Mol. Pharm. 14 (10) (2017) 3464–3472.
[13] A. Kumar, E.M. Bicer, A.B. Morgan, P.E. Pfeﬀer, M. Monopoli, K.A. Dawson,
J. Eriksson, K. Edwards, S. Lynham, M. Arno, A.F. Behndig, A. Blomberg, G. Somers,
D. Hassall, L.A. Dailey, B. Forbes, I.S. Mudway, Enrichment of immunoregulatory
proteins in the biomolecular corona of nanoparticles within human respiratory tract
lining ﬂuid, Nanomed. Nanotechnol. Biol. Med. 12 (4) (2016) 1033–1043.
[14] N.M. Davies, M.R. Feddah, A novel method for assessing dissolution of aerosol in-
haler products, Int. J. Pharm. 255 (1–2) (2003) 175–187.
[15] Y.J. Son, J.T. McConville, Development of a standardized dissolution test method
for inhaled pharmaceutical formulations, Int. J. Pharm. 382 (1–2) (2009) 15–22.
[16] W. Bernhard, J. Mottaghian, A. Gebert, G.A. Rau, H. Hardt, C. Poets, Commercial
versus native surfactants: surface activity, molecular components, and the eﬀect of
calcium, Am. J. Respir. Crit. Care Med. 162 (4) (2000) 1524–1533.
[17] S. Pham, T. Wiedmann, Dissolution of aerosol particles of budesonide in Survanta
(TM), a model lung surfactant, J. Pharmaceut. Sci. 90 (1) (2001) 98–104.
[18] A. Kumar, W. Terakosolphan, M. Hassoun, V. Kalliopi-Kelli, A. Novicky, R. Harvey,
P.G. Royall, E.M. Bicer, J. Eriksson, K. Edwards, D. Valkenborg, I. Nelissen,
D. Hassall, I.S. Mudway, B. Forbes, A biocompatible synthetic lung ﬂuid based on
human respiratory tract lining ﬂuid composition, Pharmaceut. Res. 34 (12) (2017)
2454–2465.
[19] N. Boisa, N. Elom, J.R. Dean, M.E. Deary, G. Bird, Entwistle, Development and
application of an inhalation bio-accessibility method (IBM) for lead in the PM10
size fraction of soil, Environ. Int. 70 (2014) 132–142.
[20] M.M. Nounou, L. El-Khordagui, N. Khallafallah, S. Khalil, Inﬂuence of diﬀerent
sugar cryoprotectants on the stability and physico-chemical characteristics of
freeze-dried 5-ﬂuorouracil plurilamellar vesicles, Daru 13 (4) (2005) 133–142.
[21] S. Lee, J. Lee, Y.W. Choi, Characterisation and evaluation of freeze-dried liposomes
loaded with ascorbyl palmitate enabling anti-aging therapy of the skin, Bull. Kor.
Chem. Soc. 28 (1) (2007) 99–102.
[22] X. Tang, M.J. Pikal, Design of freeze-drying processes for pharmaceuticals practical
advice, Pharmaceut. Res. 21 (2) (2004) 191–200.
[23] E.M. Bicer, Compositional Characterisation of Human Respiratory Tract Lining
Fluids for the Design of Disease Speciﬁc Simulants, PhD Thesis King’s College
London, 2015, pp. 1–428.
[24] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and puriﬁcation, Can.
J. Biochem. Physiol. 37 (8) (2011) 911–917.
[25] N. Washington, R.J.C. Steele, S.J. Jackson, D. Bush, J. Mason, D.A. Gill, K. Pitt,
D.A. Rawlins, Determination of baseline human nasal pH and the eﬀect of in-
tranasally administered buﬀers, Int. J. Pharm. (Amst.) 198 (2000) 139–146.
[26] D.R. Karnad, D.G. Mhaisekar, K.V. Moralwar, Respiraotry mucus pH in tracheoto-
mised intensive care unit patients: eﬀects of colonisation and pneumonia, Crit. Care
Med. 18 (1990) 699–701.
[27] R.M. Eﬀros, B. Peterson, R. Csaburi, J. Su, M. Dunning, J. Torday, J. Biller,
R. Shaker, Epithelial lining ﬂuid solute concenctrations in chronic obstructive lung
disease patients and normal subjects, J. Appl. Physiol. 99 (4) (2005) 1286–1292.
[28] J. Perez-Gil, K.M. Keough, Interfacial properties of surfactant proteins, Biochim.
Biophys. Acta Biomembr. 1408 (2–3) (1998) 203–217.
[29] M. Ikegamic, T.E. Weaver, S.N. Grant, J.A. Whitsett, Pulmoary surfactant surface
tension inﬂuences alveolar capillary shape and oxygenation, Am. J. Respir. Cell
Mol. Biol. 41 (4) (2009) 433–439.
[30] T.A. Siebert, S. Rugonyi, Inﬂuence of liquid-layer thickness on pulmonary surfac-
tant spreading and collapse, Biophys. J. 95 (10) (2008) 4549–4559.
[31] R. Veldhuizen, K. Nag, S. Orgeig, F. Possmayer, The role of lipids in pulmonary
surfactant, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1408 (2–3) (1998)
90–108.
[32] C. Alonso, A. Waring, J.A. Zasadzinski, Keeping lung surfactant where it belongs:
protein regulation of two-dimensional viscosity, Biophys. J. 89 (1) (2005) 266–273.
[33] L. Rey, J.C. May, third ed., Freeze Drying/lyophilisation of Pharmaceutical and
Biological products., Drugs and the Pharmaceutical Sciences vol. 206, Informa
Healthcare, UK, 2010.
[34] O.H. El-Nesr, A.S. Yahiya, O.N. El-Gazayerly, Eﬀect of formulation design and
freeze-drying on properties of ﬂuconazole multilamellar liposomes, Saudi
Pharmaceut. J. 18 (4) (2010) 217–224.
[35] S. Soares, P. Fonte, A. Costa, J. Andrade, V. Seabra, D. Ferreira, S. Reis, B. Sarmento,
Eﬀect of freeze-drying, cryoprotectants and storage conditions on the stability of
secondary structure of insulin-loaded solid lipid nanoparticles, Int. J. Pharm.
(Amst.) 456 (2) (2013) 370–381.
[36] K. Kulthanan, P. Nuchkull, S. Varothai, The pH of water from various sources: an
overview for recommendation for patients with atopic dermatitis, Asia Pac Allergy
3 (3) (2013) 155–160.
[37] P.T. Ingvarsson, M. Yang, H.M. Nielsen, J. Rantanen, C. Foged, Stabilization of li-
posomes during drying, Expet Opin. Drug Deliv. 8 (3) (2011) 375–388.
[38] E.C.A. Van Winden, Freeze-drying of liposomes: theory and practice, in: D. Nejat
(Ed.), Methods Enzyme, Academic Press, 2003, pp. 99–110.
[39] G. Mahdy, T.A. Yang, Eﬀect superheated stam on physical and lipid stability of
reconstituted whole milk powder, International Journal of Science and Research
Publications 4 (11) (2014) 1–6.
[40] W.W. Nawar, Thermal degradation of lipids, J. Agric. Food Chem. 17 (1) (1969)
18–21.
[41] A. Reis, C.M. Spickett, Chemistry of phospholipid oxidation, Biochim. Biophys. Acta
Biomembr. 1818 (10) (2012) 2374–2387.
[42] H.F. Deutsch, B.E. Kline, P. Rusch, The oxidation of phospholipids in the presence of
ascorbic acid and carcinogenic chemicals, J. Biol. Chem. 141 (1941) 529–538.
[43] M.B. Abramson, G. Colacicco, R. Curci, M.M. Rapport, Ionic properties of acidic
lipids, Phosphatidylinositol. Biochemistry 7 (5) (1968) 1692–1698.
[44] D. Jeschek, G. Lhota, J. Wallner, K. Vorauer-Uhl, A versatile, quantitative analytical
method for pharmaceutical relevant lipids in drug delivery systems, J. Pharmaceut.
Biomed. Anal. 119 (2016) 37–44.
[45] Y.Y. Xu, T. Howes, B. Adhikari, B. Bhandari, Eﬀects of emulsiﬁcation of fat on the
surface tension of protein solutions and surface properties of the resultant spray-
dried particles, Dry. Technol. 31 (16) (2013) 1939–1950.
[46] D.J. McClements, Food Emulsions: Principles, Practice and Techniques, second ed.,
CRC Press, Boca Raton, FL, 2005.
[47] H.F. Askal, A.S. Khedr, I.A. Darwich, R.M. Mahmoud, Quantitative thin-layer
chromatographic method for determination of amantadine hydrochloride, Int. J.
Biomed. Sci. 4 (2) (2008) 155–160.
M. Hassoun et al. Journal of Drug Delivery Science and Technology 47 (2018) 485–491
491
